Search Results Search Sort by RelevanceMost Recent Case and Commentary Mar 2023 How Should the US Federal Government Oversee Clinicians’ Relationships With Industry? Sunita Sah, MD, PhD, MBA Conflicts of interest must be acknowledged with sincerity and earnestness and managed such that the conflict is eliminated or, at least, credibly mitigated. AMA J Ethics. 2023;25(3):E186-193. doi: 10.1001/amajethics.2023.186. Case and Commentary Aug 2005 Finding the (Right) Time: Physician-to-Drug Rep Communication Michael E. Roloff, PhD and Rachel Malis, MA Virtual Mentor. 2005;7(8):554-558. doi: 10.1001/virtualmentor.2005.7.8.ccas5-0508. Case and Commentary Nov 2006 Distributing Drug Samples in a Free Clinic: A Personal or Policy Decision? Amanda J. Redig Virtual Mentor. 2006;8(11):729-734. doi: 10.1001/virtualmentor.2006.8.11.conl1-0611. Case and Commentary Feb 2013 Quality Improvement of Economic Profiling Marguerite Huff Virtual Mentor. 2013;125-130. doi: 10.1001/virtualmentor.2013.15.2.bndr2-1302. Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411. Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Apr 2014 Drug Samples: Why Not? Ly Le Tran, MD, JD In the view of the author, the benefits of drug sampling outweigh the risks. Virtual Mentor. 2014;16(4):245-251. doi: 10.1001/virtualmentor.2014.16.4.ecas2-1404. Pagination Current page 1 Page 2 Next page Next › Last page Last »
Case and Commentary Mar 2023 How Should the US Federal Government Oversee Clinicians’ Relationships With Industry? Sunita Sah, MD, PhD, MBA Conflicts of interest must be acknowledged with sincerity and earnestness and managed such that the conflict is eliminated or, at least, credibly mitigated. AMA J Ethics. 2023;25(3):E186-193. doi: 10.1001/amajethics.2023.186.
Case and Commentary Aug 2005 Finding the (Right) Time: Physician-to-Drug Rep Communication Michael E. Roloff, PhD and Rachel Malis, MA Virtual Mentor. 2005;7(8):554-558. doi: 10.1001/virtualmentor.2005.7.8.ccas5-0508.
Case and Commentary Nov 2006 Distributing Drug Samples in a Free Clinic: A Personal or Policy Decision? Amanda J. Redig Virtual Mentor. 2006;8(11):729-734. doi: 10.1001/virtualmentor.2006.8.11.conl1-0611.
Case and Commentary Feb 2013 Quality Improvement of Economic Profiling Marguerite Huff Virtual Mentor. 2013;125-130. doi: 10.1001/virtualmentor.2013.15.2.bndr2-1302.
Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411.
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Apr 2014 Drug Samples: Why Not? Ly Le Tran, MD, JD In the view of the author, the benefits of drug sampling outweigh the risks. Virtual Mentor. 2014;16(4):245-251. doi: 10.1001/virtualmentor.2014.16.4.ecas2-1404.